-
公开(公告)号：KR101267580B1
公开(公告)日：2013-05-28
申请号：KR1020100068558
申请日：2010-07-15
Applicant: 국립암센터
IPC: C12Q1/68 , C12N15/11 , G01N33/574
CPC classification number: C12Q1/6886 , C12Q2600/158
Abstract: 본발명은신장암의바이오마커로서 TGase2(Transglutaminase 2) 및 VHL(Von Hippel-Lindau)에관한것으로, 보다구체적으로 TGase2 및 VHL 중하나이상의발현수준을측정하는제제를포함하는신장암진단용조성물및 상기조성물을포함하는신장암진단용키트에관한것이다. 또힌본 발명은신장암진단에필요한정보를제공하기위하여, 신장암이의심되는환자의시료로부터 TGase2 및 VHL 중하나이상의발현수준을측정하는단계; 및상기 TGase2 및 VHL 중하나이상의발현수준을정상대조구시료의 TGase2 및 VHL 중하나이상의발현수준과비교하는단계를포함하는신장암마커 TGase2 및 VHL 중하나이상을검출하는방법에관한것이다.
-
公开(公告)号：KR1020110006534A
公开(公告)日：2011-01-20
申请号：KR1020090064219
申请日：2009-07-14
Applicant: 국립암센터
IPC: A61K31/194 , A61K31/336 , A61P35/00 , A61P29/00
Abstract: PURPOSE: A method for inducing remodeling keratin in cancer cells or inflammatory cells is provided to develop a therapeutic agent for metastatic cancer. CONSTITUTION: A compound of chemical formula 1 or 2 is used for inducing keratin remodeling in cancer cells or inflammatory cells. A method for screening an anticancer drug comprises: a step of simultaneously or gradually treating the compound and test compound to cancer cells; a step of measuring keratin remodeling degree in the cancer cells; and a step of determining a compound which functions as an inhibitor for cancer metastasis in case of suppressing keratin remodeling by treatment of the test compound. A composition for inducing cancer metastasis contains the compound of chemical formula 1 or 2.
Abstract translation: 目的：提供一种在癌细胞或炎性细胞中诱导重塑角蛋白的方法，以开发转移性癌症的治疗剂。 构成：化学式1或化合物2用于诱导癌细胞或炎性细胞中的角蛋白重塑。 筛选抗癌药物的方法包括：同时或逐渐地将所述化合物和试验化合物处理至癌细胞的步骤; 测定癌细胞角蛋白重塑度的步骤; 以及在通过治疗化合物抑制角蛋白重塑的情况下，测定作为癌症转移抑制剂起作用的化合物的工序。 用于诱导癌症转移的组合物含有化学式1或化合物2。
-
公开(公告)号：KR1020100067170A
公开(公告)日：2010-06-21
申请号：KR1020080125616
申请日：2008-12-11
Applicant: 국립암센터 , 강원대학교산학협력단
IPC: A61K31/7028 , A61P9/14
CPC classification number: A61K31/7028
Abstract: PURPOSE: A glucosamine or derivative thereof is provided to prevent or treat angiostenosis and restenosis and to treat heart diseases without surgery. CONSTITUTION: A composition for preventing or treating angiostenosis and restenosis contains glucosamine, glucosamine derivative, or salt thereof. The glucosamine derivative is a compound of chemical formula 2. In chemical formula 2, R is acyl group of 2-18 carbon atoms or straight or branched alkyl group of 1-5 carbon atoms. The composition containing glucosamine is administered for preventing or treating angiosternosis and restenosis. The glucosamine or glucosamine derivative is administered through oral or parenteral route. The glucosamine or glucosamine derivative is topically administered to a blood vessel.
Abstract translation: 目的：提供葡糖胺或其衍生物以预防或治疗血管狭窄和再狭窄并且在不手术的情况下治疗心脏病。 构成：用于预防或治疗血管狭窄和再狭窄的组合物含有葡糖胺，葡糖胺衍生物或其盐。 葡糖胺衍生物是化学式2的化合物。在化学式2中，R是2-18个碳原子的酰基或1-5个碳原子的直链或支链烷基。 给予含有葡糖胺的组合物用于预防或治疗血管性异位症和再狭窄。 葡萄糖胺或葡糖胺衍生物通过口服或非肠道途径给药。 将葡糖胺或葡糖胺衍生物局部施用于血管。
-
34.发明公开에타크리닉 산을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 无效用于预防或治疗包含乙酸的转谷氨酰胺酶相关疾病的药物组合物，以及使用该方法预防或治疗转谷氨酰胺酶相关疾病的方法
公开(公告)号：KR1020100060189A
公开(公告)日：2010-06-07
申请号：KR1020080118688
申请日：2008-11-27
Applicant: 국립암센터
IPC: A61K31/192 , A61P35/00
CPC classification number: A61K31/192
Abstract: PURPOSE: A transglutaminase inhibitor containing ethacrynic acid and a pharmaceutically acceptable salt thereof is provided to prevent and treat transglutaminase overexpression-related diseases without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases caused by enhanced transglutaminase activation contains ethacrynic acid or a pharmaceutically acceptable salt thereof. Diseases are inflammatory diseases, cancer, or neural disorders. The inflammatory disease is chronic inflammatory disease, sepsis, or autoimmunity myositis. The neural disorder is Alzheimer disease, Huntingtun disease, or Parkinson's disease.
Abstract translation: 目的：提供含有ethacrynic酸及其药学上可接受的盐的转谷氨酰胺酶抑制剂，用于预防和治疗转谷氨酰胺酶过表达相关疾病而没有副作用。 构成：用于预防或治疗由增强的转谷氨酰胺酶活化引起的疾病的药物组合物含有乙酰酸或其药学上可接受的盐。 疾病是炎性疾病，癌症或神经障碍。 炎性疾病是慢性炎性疾病，败血症或自身免疫性肌炎。 神经障碍是阿尔茨海默病，亨廷顿病或帕金森病。
-
35.发明公开썰파렘을 포함하는 트란스글루타미나제 관련 질환 예방 또는 치료용 조성물 및 그를 이용하는 트란스글루타미나제 관련 질환 예방 또는 치료 방법 无效一种用于预防或治疗包含苏氨酸的转氨酶相关疾病的药物组合物，以及使用该方法预防或治疗转氨酶相关性疾病的方法
公开(公告)号：KR1020100056212A
公开(公告)日：2010-05-27
申请号：KR1020080115280
申请日：2008-11-19
Applicant: 국립암센터
IPC: A61K31/385 , A61K31/381 , A61P35/00
Abstract: PURPOSE: A transglutaminase inhibitor containing sulfarlem is provided to apply to a patient with abnormal transglutaminase overexpression and to suppress transglutaminase without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating diseases caused by transglutaminase activation contains sulfarlem or pharmaceutically acceptable salt thereof. The diseases are inflammatory diseases, cancers, or neurological disorders. The composition has anti-metastasis effect. The inflammatory diseases are chronic inflammatory disease such as degenerative arthritis, septicemia, or autoimmune myositis. The neurological disorders are Alzheimer diseases, Huntington disease, or Parkinson's disease.
Abstract translation: 目的：提供含有sulfarlem的转谷氨酰胺酶抑制剂以适用于转谷氨酰胺转氨酶异常反应的患者，并抑制转谷氨酰胺酶无副作用。 构成：用于预防或治疗由转谷氨酰胺酶活化引起的疾病的药物组合物含有磺胺类或其药学上可接受的盐。 疾病是炎性疾病，癌症或神经系统疾病。 该组合物具有抗转移作用。 炎性疾病是慢性炎症性疾病，如退行性关节炎，败血症或自身免疫性肌炎。 神经障碍是阿尔茨海默病，亨廷顿病或帕金森病。
-
Patent Agency Ranking
公开(公告)号：KR100947209B1
公开(公告)日：2010-03-11
申请号：KR1020070098862
申请日：2007-10-01
Applicant: 국립암센터
IPC: A61K31/216 , A61P35/00
CPC classification number: A61K31/216
Abstract: 본 발명은 클로로겐산 또는 그 유도체를 포함하는 항암감작제에 관한 것으로, 보다 구체적으로는 항암제를 투여하여 암을 치료하는 경우 항암제의 효과를 높여주는 클로로겐산 또는 그 유도체를 포함하는 항암감작제에 관한 것이다. 또한, 본 발명은 클로로겐산 또는 그 유도체 및 약제학적으로 허용되는 담체를 포함하는 항암제 내성 저해용 조성물, 상기 조성물에 추가적으로 항암제를 포함하는 항암조성물 및 상기의 항암감작제를 투여하여 항암제내성을 극복하는 방법에 관한 것이다.
항암감작제, 클로로겐산, 항암제 내성-
公开(公告)号：KR1020100011620A
公开(公告)日：2010-02-03
申请号：KR1020080072911
申请日：2008-07-25
Applicant: 국립암센터
Abstract: PURPOSE: A composition containing curcumin for suppressing transglutaminase is provided to prevent and treat diseases induced by abnormal activity of the transglutaminase without side effects. CONSTITUTION: A pharmaceutical composition for preventing or treating neural diseases or inflammatory diseases caused by transglutaminase activation. The curcumin is denoted by chemical formula 1 and isolated from Curcuma longa L. Neural diseases is Alzheimer disease, multi-infarct dementia, hypothyrodism, alcoholic dementia, huntington disease or Parkinson's disease. Inflammatory diseases is degenerative arthritis, diabetes, autoimmunity myositis, arteriosclerosis, cerebral apoplexy, liver hardening, meningitis, inflammatory gastric ulcer, sinusitis, rhinitis, conjunctivitis, asthma, skin inflammatory disease, inflammatory bowel disease, rheumatic inflammation disease, and inflammatory collagen vascular disease.
Abstract translation: 目的：提供含有姜黄素抑制转谷氨酰胺酶的组合物，用于预防和治疗由转谷氨酰胺酶异常活动引起的疾病，无副作用。 构成：用于预防或治疗由转谷氨酰胺酶活化引起的神经疾病或炎性疾病的药物组合物。 姜黄素由化学式1表示，分离自姜黄L.神经疾病是阿尔茨海默病，多发性梗死性痴呆，甲状腺功能低下，酒精性痴呆，亨廷顿疾病或帕金森病。 炎性疾病是退行性关节炎，糖尿病，自身免疫性肌炎，动脉硬化，脑中风，肝硬化，脑膜炎，炎性胃溃疡，鼻窦炎，鼻炎，结膜炎，哮喘，皮肤炎性疾病，炎性肠病，风湿性炎症疾病和炎性胶原血管病 。
-
公开(公告)号：KR1020090033699A
公开(公告)日：2009-04-06
申请号：KR1020070098862
申请日：2007-10-01
Applicant: 국립암센터
IPC: A61K31/216 , A61P35/00
CPC classification number: A61K31/216
Abstract: A cancer sensitizer containing chlorogenic acid or derivative thereof is provided to show improved effects of cancer treatment and lower anti-cancer drug tolerance of cancer cells, thereby increasing sensitivity of the anti-cancer drug. A composition for inhibiting anti-cancer drug tolerance comprises chlorogenic acid or derivative thereof and a pharmaceutically allowable carrier. A composition for treating cancer contains the composition for inhibiting anti-cancer drug tolerance and anti-cancer drug. The anti-cancer drug is selected from the group consisting of mechloethamine, chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine, lomustine, streptozotocin, busulfan, thiotepa, cisplatin, carboplatin, dactinomycin, doxorubicin, daunorubicin, idarubicin, mitoxantrone, plicamycin, mitomycin, C Bleomycin, vincristine, vinblastine, paclitaxel, docetaxel, etoposide, teniposide, topotecan and iridotecan.
Abstract translation: 提供含有绿原酸或其衍生物的癌症敏化剂，以显示癌症治疗的改善效果和较低的癌细胞的抗癌药物耐受性，从而增加抗癌药物的敏感性。 用于抑制抗癌药物耐受性的组合物包括绿原酸或其衍生物和药学上可允许的载体。 用于治疗癌症的组合物含有用于抑制抗癌药物耐受性和抗癌药物的组合物。 抗癌药选自甲氯胺素，苯丁酸氮芥，苯丙氨酸，芥子，环磷酰胺，异环磷酰胺，卡莫司汀，洛莫司汀，链脲霉素，白消安，噻替派，顺铂，卡铂，更生霉素，多柔比星，柔红霉素，伊达比星，米托蒽醌， 丝裂霉素，博来霉素，长春新碱，长春花碱，紫杉醇，多西他赛，依托泊苷，替尼泊苷，托泊替康和依立替康。
-
公开(公告)号：KR1020080108797A
公开(公告)日：2008-12-16
申请号：KR1020070056812
申请日：2007-06-11
Applicant: 국립암센터
IPC: A61K31/353 , A61P25/00
CPC classification number: A61K31/353
Abstract: A pharmaceutical composition comprising a transglutaminase inhibitor containing EGCG(epigallocatechin gallate) is provided to cure the disease caused by the increment of transglutaminase activity. The transglutaminase inhibitor is comprised of the epigallocatechin gallate(EGCG) or its derivatives. The activity of transglutaminase is suppressed by using EGCG or its derivative. The pharmaceutical composition for treating the disease caused by the increment of transglutaminase activity comprises the epigallocatechin gallate(EGCG) or its derivatives, wherein the disease is nervous system disorders including Alzheimer's disease, Huntington's disease and Parkinson's disease or cancer.
Abstract translation: 提供包含含有EGCG（表儿儿茶素没食子酸酯）的转谷氨酰胺酶抑制剂的药物组合物以治愈由转谷氨酰胺酶活性增加引起的疾病。 转谷氨酰胺酶抑制剂由表没食子儿茶素没食子酸酯（EGCG）或其衍生物组成。 通过使用EGCG或其衍生物抑制转谷氨酰胺酶的活性。 用于治疗由转谷氨酰胺酶活性增加引起的疾病的药物组合物包括表没食子儿茶素没食子酸酯（EGCG）或其衍生物，其中疾病是神经系统疾病，包括阿尔茨海默病，亨廷顿病和帕金森病或癌症。
-
公开(公告)号：KR100838715B1
公开(公告)日：2008-06-16
申请号：KR1020060098921
申请日：2006-10-11
Applicant: 국립암센터
IPC: C07K14/00
CPC classification number: C12N9/1044 , A61K38/00 , C07K14/4705
Abstract: 본 발명은 트란스글루타미나제 억제제에 관한 발명으로서, 구체적으로는 트란스글루타미나제를 억제하는 펩타이드를 제공하고, 상기 펩타이드 또는 이를 포함하는 트란스글루타민 억제용 조성물 및 이들을 이용하여 트란스글루타미나제를 억제하는 방법, 바람직하게는 트란스글루타미나제를 억제함으로써 다양한 염증 및 암 질환을 치료하는 방법을 제공한다. 또한, 본 발명은 상기 펩타이드의 변이체를 제조하는 방법을 제공한다.
본 발명의 펩타이드 또는 이를 포함하는 약제학적 조성물은 트란스글루타미나제의 비정상적 활성에 의해 유도된 질환, 구체적으로 염증질환과 암을 효과적으로 예방 및 치료할 수 있다.
I-kappaBalpha(I-κBα), 트란스글루타미나제, 핵인자 카파 비(Nuclear factor-kappaB, NF-κB), 염증, 암
-
-
-
-
-
-
-
-
-
Search Results
67
records
(took 0.026 seconds)
